



Press Release

ERYtech Pharma announces appointment of Marc Beer to the Supervisory Board

Lyon (France), Philadelphia (USA), February 17th, 2011. ERYtech Pharma, an emerging specialty pharma company, is pleased to welcome Marc Beer as a new board member.

Marc Beer is CEO of Aegerion Pharmaceuticals since August 2010. Prior to this, he was founder and CEO of Viacell, a biotechnology company specialized in the collection and preservation of umbilical cord blood stem cells. Before creating Viacell, Marc Beer held several senior positions both in global marketing and business development, including being responsible for the global launch of several products for orphan diseases as Vice President of Global Marketing within Genzyme's therapeutics division. He has also held the position of VP, Sales & Marketing at Biostar, Inc. as well as senior management positions in the Pharmaceutical and Diagnostic divisions of Abbott Laboratories. He serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Body, he is Chairman of Good Start Genetics, and a member of the board of Seaside Therapeutics.

“We are proud to welcome Marc Beer to our Supervisory Board. We have been fortunate to work with Marc in the past on Business Development projects and as a member of our management team. His experience and network in the US biotechnology and pharmaceutical industry is of great value to us as we pursue our international development” said Sven Andréasson, Chairman of ERYtech.

Marc Beer said: “I’m excited to join the ERYtech board. I feel close to the company thanks to our prior collaboration on Business Development projects. ERYtech Pharma has a unique technology and products in development that have the potential to fulfill high unmet medical needs in many significant areas. I look forward to assisting the company on its way to become a successful commercial organization”.

[About ERYtech Pharma \(http://www.erytech.com/\)](http://www.erytech.com/)

ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of hematology, cancer and metabolic diseases. ERYtech Pharma’s lead product in late-stage clinical development, Graspera®, is aimed at treating severe adult & elderly patients suffering from acute lymphoblastic leukemia as a first indication.

ERYtech Pharma: Pierre-Olivier Goineau, CEO

60, av Rockefeller- Bâtiment Adénine -69008
Lyon - France
Tel : + 33 (0)4 78 74 44 38
contact@erytech.com

ERYtech Pharma US Office:

3711 Market Street, 19104 Philadelphia PA -
USA